Skip to content

Preferred Stock at other companies

Merit Medical Systems logo
Merit Medical SystemsMMSI
$0
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$0
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$0
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$0
PVL
Palvella TherapeuticsPVLA
$0
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$0

Other financials

Income statement

See full
Revenue$401.0K
Gross profit$31.0K
Operating income-$19.2M-6.1%
Net income-$18.6M-10.6%
EPS (diluted)-$0.49-2.1%

Balance sheet

See full
Cash & equivalents$68.3M-42.7%
Total debt$7.2M-16.6%
Total equity$66.3M-44.0%
Total assets$81.6M-38.8%

Cash flow

See full
Operating cash flow-$14.6M-7.9%
CapEx$33.0K-26.7%
Free cash flow-$14.6M-7.8%

Valuation

See full
Market cap$1.77B+38.4%

Profitability

See full
Gross margin-4,067.5%
Operating margin-10,392.1%
Net margin-9,929%
FCF margin-7,390%

Returns & leverage

See full
Return on equity-80.7%+3.1pp
Debt / equity0.1×0.0×
Current ratio7.3×-8.3×

Where this comes from

Reported directly by Pulse Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Pulse Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Pulse Biosciences, Inc.'s preferred stock?
Pulse Biosciences, Inc. (PLSE) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.